{"entity":{"id":"fgf19","kind":"target","name":"FGF19","aka":["fibroblast growth factor 19","Fibroblast growth factor 19"],"tldr":"FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.","summary":"Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.\n\nCIViC holds 5 clinical evidence items and 0 assertions across 4 variants, naming Sorafenib, FGFR4 Inhibitor H3B-6527 and Fisogatinib.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3675","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3675"},{"label":"UniProt O95750","url":"https://www.uniprot.org/uniprotkb/O95750/entry"},{"label":"NCBI Gene 9965","url":"https://www.ncbi.nlm.nih.gov/gene/9965"},{"label":"Ensembl ENSG00000162344","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162344"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["hcc","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07327034","nct07547553"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 5 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FGF19","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3675","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3675","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O95750","url":"https://www.uniprot.org/uniprotkb/O95750/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FGF19","url":"https://civicdb.org/features/7909","note":"5 evidence items, 0 assertions, 4 variants; diseases: Hepatocellular Carcinoma, Ovarian Cancer (GraphQL API, CC0)"}],"distribution":"few-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FGF19: RNA tissue enriched (gallbladder 223 nTPM); high antibody staining in 6 normal tissues; highest cancer staining head and neck cancer (1 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Hepatocellular carcinoma, Ovarian cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas FGF19 tissue","url":"https://www.proteinatlas.org/ENSG00000162344-FGF19/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000162344 associations","url":"https://platform.opentargets.org/target/ENSG00000162344/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3675","ensembl":"ENSG00000162344","uniprot":"O95750","entrez":"9965","firstDescribed":1999,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Nishimura et al, Biochim. Biophys. Acta, 1999, \"Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9931477/","biology":"Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4. Location: Secreted (UniProt). Locus 11q13.3 (HGNC).","whereFound":["Hepatocellular carcinoma: CIViC evidence names this disease","Ovarian cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/fgf19/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"trial":[{"id":"nct07547553","kind":"trial","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","route":"/trials/nct07547553/"},{"id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","route":"/trials/nct07327034/"}]}}